Internal Quality Control in Hemostasis Assays

Abstract

Internal quality control (IQC) for routine and specialist hemostasis testing represents a mandatory requirement for assays offered by clinical laboratories under International Organization for Standardization, Code of Federal Regulations, and Clinical and Laboratory Standards Institute standards. The underlying principle is that regular IQC audits the analytical performance of automated, semiautomated, and manual methods. This review investigates IQC practices, including benefits, limitations, frequency per time period or batch, sources of material used, primary supplier, third party or in-house, plus troubleshooting when IQC falls outside acceptance criteria. To assess IQC practice, the UK National External Quality Assessment Scheme (NEQAS) Blood Coagulation distributed a questionnaire to 1,200 participants enrolled in our scheme that collected details of the local practices for IQC testing. We received returns from 127 centers that described their local practices for the frequency of IQC, the type of IQC material employed, acceptance criteria for IQC data, and troubleshooting protocols for IQC failures. The data collected as part of an NEQAS BC questionnaire confirmed that all the participants returning answers to the questionnaire meet the standards for regular IQC testing for the hemostasis assays they perform.

Keywords

internal quality control - hemostasis assays - troubleshooting

Publication History

Article published online:
25 September 2023

• References

• 1 Kitchen S, Olson JD, Preston EF. eds. Quality in Laboratory Haemostasis and Thrombosis. 1st ed.. 2009: 11
• 2 Castaman G, Hillarp A, Goodeve A. Laboratory aspects of von Willebrand disease: test repertoire and options for activity assays and genetic analysis. Haemophilia 2014; 20 Suppl 4 (04) 65-70
• 3 Kinns H, Pitkin S, Housley D, Freedman DB. Internal quality control: best practice. J Clin Pathol 2013; 66 (12) 1027-1032
• 4 ISO 15189. Medical laboratories—requirements for quality and competence. Geneva, Switzerland: International Organization for Standardization; ; Fourth edition 2022–12
• 5 CLSI. One-stage prothrombin time (PT) test and activated partial thromboplastin time (APTT) Test, 2nd Edition. In: One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test; Approved Guideline—2nd Edition
• 6 Code of Federal Regulations Title 42, Chapter IV, Subchapter G, Part 493, Subpart K, Analytical systems 493.1269 (b)
• 7 Werfen Field Safety Notice (Medicines and Healthcare products Regulatory Agency (filecamp.com)
• 8 Thermo Fisher Field Safety International Medical Devices Database (icij.org)
• 9 Baker P, Platton S, Gibson C. et al; British Society for Haematology, Haemostasis and Thrombosis Task Force. Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Br J Haematol 2020; 191 (03) 347-362
• 10 Jennings I, Kitchen DP, Woods TA, Kitchen S, Preston FE, Walker ID. Stability of coagulation proteins in lyophilized plasma. Int J Lab Hematol 2015; 37 (04) 495-502
• 11 Internal quality control in routine analysis (rsc.org). February 2010. Accessed August 21, 2023 at: https://www.rsc.org/images/internal-quality-control-routine-analysis-technical-brief-46_tcm18-214818.pdf
• 12 The Association for Clinical Biochemistry and Laboratory Medicine. IQC-for-Networked-Analysers-user-guide.pdf. 25th September 2020. Accessed August 21, 2023 at: https://www.acb.org.uk/asset/D9E1AD09-09A2-41B8-BCBD10A4F75EC11C/